Nov 05, 2019
Amgen has announced to purchase 20.5% of the stake in Chinese-American drug company BeiGene. As per the deal signed, Amgen will develop and commercialize around two dozen of its on-market as well as experimental drug compounds for the treatment of cancer in China. The shares purchased are worth USD 2.7 bill...
Read More...
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Newsletter/Whitepaper